CANC
Tema Oncology ETF
Price Chart
Latest Quote
$37.19
-0.28 (-0.73%)
Current Price
| Previous Close | $37.47 |
| Open | $37.38 |
| Day High | $37.78 |
| Day Low | $36.69 |
| Volume | 29,581 |
Fund Information
| Quarterly Dividend / Yield | N/A / 0.05% |
| Net Assets | $176.14M |
| Expense Ratio | 0.75% |
| Category | Health |
| Fund Family | Tema Global Limited |
| Net Asset Value | $37.48 |
| Premium/Discount | -0.77% |
| Quarterly Dividend Yield | 0.05% |
| P/E Ratio | 23.39 |
| Exchange | NGM |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $37.30 |
| SMA50 | $37.71 |
| SMA200 | $34.63 |
| RSI | 43.17 |
| ATR | 0.8761 |
| Rel Volume | 1.34 |
Performance History
| Week | -0.18% |
| Month | +1.23% |
| Quarter | +4.04% |
| 6 Months | +7.08% |
| YTD | +7.52% |
| Year | +50.08% |
| 10 Years | +956.89% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $37.19 | 29,500 |
| 2026-06-17 | $37.47 | 12,900 |
| 2026-06-16 | $37.18 | 10,400 |
| 2026-06-15 | $37.47 | 14,400 |
| 2026-06-12 | $37.48 | 12,000 |
| 2026-06-11 | $37.26 | 10,700 |
| 2026-06-10 | $36.48 | 45,200 |
| 2026-06-09 | $36.79 | 16,800 |
| 2026-06-08 | $36.12 | 9,600 |
| 2026-06-05 | $36.43 | 26,100 |
| 2026-06-04 | $37.25 | 17,200 |
| 2026-06-03 | $36.40 | 43,500 |
| 2026-06-02 | $36.37 | 59,000 |
| 2026-06-01 | $37.26 | 35,200 |
| 2026-05-29 | $38.09 | 17,400 |
| 2026-05-28 | $38.30 | 27,600 |
| 2026-05-27 | $38.09 | 10,300 |
| 2026-05-26 | $38.06 | 24,800 |
| 2026-05-22 | $38.12 | 9,200 |
| 2026-05-21 | $38.14 | 9,200 |
| 2026-05-20 | $37.68 | 10,400 |
| 2026-05-19 | $36.74 | 7,100 |
About Tema Oncology ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.